Cleavage of survivin by Granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells.
Granzyme M (GzmM) is a chymotrypsin-like serine protease that preferentially cuts its substrates after Met or Leu. GzmM is constitutively expressed in activated innate effector natural killer (NK) cells. GzmM-induced cell death is consistent with the kinetics of cytotoxicity of NK cells. These suggest that GzmM may play an important role in innate immunity. Our previous work demonstrated that GzmM induces caspase-dependent apoptosis. However, it is unknown about how GzmM causes caspase activation. Here, we showed that the inhibitor of the apoptosis gene family member Survivin is a physiological substrate for GzmM. GzmM hydrolyzes Survivin at Leu-138 to remove the last four C-terminal residues. The truncated form (sur-TF) is more rapidly hydrolyzed through proteasome-mediated degradation. In addition, Survivin is in complex with X-linked inhibitor of apoptosis protein (XIAP) to inhibit caspase activation as an endogenous inhibitor. Survivin cleavage by GzmM abolishes the stability of the Survivin-XIAP complex and enhances XIAP hydrolysis, which amplifies caspase-9 and 3 activation of target tumor cells. The noncleavable L138A Survivin overexpression can significantly inhibit GzmM-mediated XIAP degradation, caspase activation, and GzmM- and NK cell-induced cytotoxicity. Moreover, Survivin silencing promotes XIAP degradation and enhances GzmM-induced caspase activation as well as GzmM- and NK cell-induced cytolysis of target tumor cells.
Hu
Deqing
D
National Laboratory of Biomacromolecules and Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Liu
Shengwu
S
Shi
Lei
L
Li
Chong
C
Wu
Lianfeng
L
Fan
Zusen
Z
D053453:Caspase 9 / Q000378:metabolism; D020169:Caspases / Q000378:metabolism*; D004789:Enzyme Activation; D020868:Gene Silencing; D053804:Granzymes / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D006868:Hydrolysis; D051034:Inhibitor of Apoptosis Proteins; D019169:Jurkat Cells; D007930:Leucine / Q000737:chemistry; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000378:metabolism*; D034622:RNA Interference; D000077022:Survivin; D020798:Two-Hybrid System Techniques; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000378:metabolism*
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin; D051636:X-Linked Inhibitor of Apoptosis Protein; D053804:Granzymes; D053453:Caspase 9; D020169:Caspases; D007930:Leucine
J Biol Chem. 1998 Jan 30;273(5):2910-6
9446602
J Biol Chem. 2007 Jul 13;282(28):20553-60
17513296
Annu Rev Cell Dev Biol. 1999;15:269-90
10611963
Genomics. 1994 Dec;24(3):445-50
7713495
Cell Death Differ. 2007 Mar;14(3):489-99
17008916
J Biol Chem. 2004 Dec 24;279(52):54275-82
15494398
Nat Rev Cancer. 2008 Jan;8(1):61-70
18075512
J Biol Chem. 2004 Aug 13;279(33):34087-90
15218035
J Immunol. 2001 Jan 15;166(2):765-71
11145648
J Biol Chem. 2006 Aug 25;281(34):24721-7
16807248
Curr Opin Cell Biol. 2006 Dec;18(6):609-15
16934447
Nat Immunol. 2002 Jan;3(1):83-90
11743585
Blood. 2003 May 1;101(9):3590-3
12506019
Nat Struct Biol. 2000 Jul;7(7):602-8
10876248
Cell Death Differ. 1999 Nov;6(11):1028-42
10578171
Mol Cell. 2007 Jul 6;27(1):17-28
17612487
Blood. 2006 Feb 15;107(4):1342-51
16223768
J Immunol. 2006 Jul 15;177(2):1171-8
16818775
J Biol Chem. 2003 Jun 20;278(25):23130-40
12660240
J Immunol. 2009 Jul 1;183(1):421-9
19542453
Nat Med. 1997 Aug;3(8):917-21
9256286
Exp Hematol. 2005 Oct;33(10):1160-71
16219538
J Biol Chem. 2004 May 21;279(21):22236-42
15028722
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5679-83
7777569
EMBO J. 2003 Jun 2;22(11):2729-40
12773388
Science. 2002 Apr 19;296(5567):550-3
11910072
EMBO Rep. 2006 Oct;7(10):988-94
17016456
Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10
12042762
J Biol Chem. 2008 Nov 7;283(45):30796-803
18784078